Hangzhou's Eli Radiopharma Raises $56M Series A Led by Huagai Capital to Push Cancer and Brain Radiopharmaceuticals Toward the Clinic

The two-year-old Chinese biotech says several programs are nearing IND submission after a round that drew more than a dozen investors.

Eli Radiopharma, a Hangzhou, China-based developer of radiopharmaceuticals for cancer and neurological diseases, has completed a Series A financing of nearly RMB 400 million (about $56 million). Huagai Capital led the round with Bayland Capital as co-lead, the company announced on November 11, 2026.


Who Invested


Huagai Capital led and Bayland Capital co-led. New investors include Boyu Ventures, Delian Capital, InnoPinnacle Fund, Haibang Venture, Bairui Capital, Shenzhen Angel FOF Management and Grand Flight Investment.


Existing shareholders CSPC & Growth Bio Fund, Huaige Capital, KHK Fund, Longfeng Venture, Hongsheng Capital, Bioclub Fund and Skyfield Capital also took part. Valuation was not disclosed.


What Eli Radiopharma Does


Founded in 2024 by CEO Dr. Feng Yu, Eli Radiopharma develops theranostics, drugs that pair a molecule designed to find a specific target in the body with a radioactive isotope. Depending on the isotope, the same approach can be used to image a disease or to deliver radiation directly to diseased cells. The company is focused on oncology and neurological diseases.


Traction


Eli Radiopharma is preclinical. Multiple programs aimed at novel molecular targets have moved through lead discovery and both in vitro and in vivo validation, and the company says several are approaching IND submission, the regulatory step required before human trials.


The Series A follows a round of nearly RMB 100 million that the company announced in March 2026. It has not disclosed revenue or partnership terms.


What the Money Is For


Proceeds will fund preclinical research, clinical trial applications and early-stage clinical development. The company also plans to expand its R&D platforms, hire talent and build out clinical and business development.


Why It Matters


Radiopharmaceuticals have become one of the hottest corners of oncology, with large drugmakers paying up for platforms and pipelines in recent years. China has emerged as a fast-growing hub for the field, and investors there are backing young companies at a steady clip. By one count from Caixin, China had nearly 100 nuclear medicine companies in 2024, up from about 20 in 2019.


Raising roughly $56 million in a Series A, two years after founding and before any human trials, signals how much conviction investors have in the space. The neurological focus is a notable twist in a field that has mostly centered on cancer. The next milestone is clear: getting its first programs through IND and into the clinic.


Source


PR Newswire — "Eli Radiopharma Completes Series A Financing of Nearly RMB 400 Million to Advance Innovative Radiopharmaceutical Pipeline Toward Clinical Development"

0 Comments